Taylor PC, et al. - Authors drew a comparison between sirukumab monotherapy (an anti–interleukin-6 cytokine monoclonal antibody) and adalimumab monotherapy in patients with rheumatoid arthritis (RA). Compared to adalimumab monotherapy, sirukumab monotherapy showed greater improvements in DAS28 (ESR), but similar ACR50 response rates. The safety profile of sirukumab was consistent with that observed with anti-interleukin-6 receptor antibodies. With sirukumab, a dose-related impact on the incidence of injection-site reactions was observed.